<DOC>
	<DOCNO>NCT02097342</DOCNO>
	<brief_summary>This study plan evaluate linagliptin improve insulin sensitivity patient type 2 diabetes mellitus . In addition , effect linagliptin pancreatic function study .</brief_summary>
	<brief_title>Effect Linagliptin Insulin Sensitivity Pancreatic Beta Cell Function Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This prospective study 30 patient type 2 diabetes mellitus ( T2DM ) . Patients T2DM age group 30-65 year duration diabetes less five year screen . After exclusion , meet inclusion criterion include study . Once eligibility criterion confirm , patient educate disease advise weight maintenance diabetic diet exercise throughout study period . Patients randomize three group - linagliptin ( 5mg OD ) voglibose ( 0.2mg TDS ) placebo OD . Metformin continue patient . To evaluate effect linagliptin insulin sensitivity beta cell function , independent change HbA1c , voglibose group include . Each group 10 patient follow 6 month . Both patient physician blind treatment . After write informed consent , detailed history thorough clinical examination do subject include measurement height , weight , body mass index waist circumference . Hemoglobin , liver function test , renal function test , lipid profile , HbA1c , fast plasma insulin , C-peptide , homeostasis model assessment-insulin resistance index ( HOMA-1R ) homeostasis model assessment-beta cell function index ( HOMA-Î² ) do baseline . A euglycemic hyperinsulinemic clamp study mixed meal test perform patient ( different day ) baseline 6 month follow . Biochemical parameter measure 6 month therapy . Fasting post-prandial blood glucose do monthly 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Patients type 2 diabetes mellitus ( accord ADA guideline ) Age 3065 year Duration diabetes less five year BMI 20 40 kg/m2 HbA1c level &lt; 7.5 % On metformin monotherapy least 6 week History ketoacidosis Hepatic impairment ( define plasma aminotransferase elevation 3 time upper limit normal ) Renal failure ( define Serum Creatinine 1.5 mg/dl ) Coronary artery disease heart failure Cerebrovascular disease stroke Anemia ( Hb &lt; 10 g/dl ) Those require insulin therapy HbA1c &gt; 7.5 % Presence macular edema Pregnant lactate woman Patients receive dipeptidyl peptidase 4 ( DPP4 ) inhibitor therapy within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Insulin sensitivity- hyperinsulinemic euglycemic clamp</keyword>
	<keyword>Pancreatic beta cell function</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>Voglibose</keyword>
	<keyword>Mixed meal test</keyword>
	<keyword>GLP-1 response</keyword>
</DOC>